Literature DB >> 21990116

Gadoxetic acid-enhanced MRI findings of early hepatocellular carcinoma as defined by new histologic criteria.

Hyungjin Rhee1, Myeong-Jin Kim, Young Nyun Park, Jin-Sub Choi, Kyung-Sik Kim.   

Abstract

PURPOSE: To describe the imaging features of early hepatocellular carcinoma (HCC) on gadoxetic acid-enhanced MRI (Gd-EOB-MRI) in comparison with multidetector computed tomography (MDCT) examinations.
MATERIALS AND METHODS: We analyzed imaging findings of 19 pathologically proven early HCC lesions in 15 patients who underwent both MDCT and Gd-EOB-MRI at 3.0 Tesla (T) units before surgery. MRI included in-phase and out-of-phase T1-weighted dual-echo gradient-recalled-echo sequences, dynamic T1-weighted images before and after bolus injection of gadoxetic acid disodium, fat-saturated T2-weighted fast spin-echo sequences, and T1-weighted hepatobiliary phase images 20 min after contrast injection. Two radiologists retrospectively evaluated the signal intensities and enhancement features on MRI and MDCT.
RESULTS: None of the lesions displayed arterial enhancement and washout on MDCT. On Gd-EOB-MRI, six (32%) lesions showed T2-hyperintensity, five (26%) lesions showed signal drop on opposed-phase. Three lesions (16%) showed arterial enhancement and washout. Twelve (63%), 13 (68%), and 15 (79%) lesions were hypointense on hepatic venous, equilibrium, and hepatobiliary phase, respectively.
CONCLUSION: Most early HCCs did not show arterial enhancement and washout pattern on both MDCT and Gd-EOB-MRI. Gd-EOB-MRI may provide several ancillary findings for diagnosis of early HCC such as decreased hepatobiliary uptake, T2 hyperintensity and signal drop in opposed phase.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21990116     DOI: 10.1002/jmri.22828

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  16 in total

1.  The essence of the Japan Radiological Society/Japanese College of Radiology Imaging Guideline.

Authors:  Yasuyuki Yamashita; Sadayuki Murayama; Masahiro Okada; Yoshiyuki Watanabe; Masako Kataoka; Yasushi Kaji; Keiko Imamura; Yasuo Takehara; Hiromitsu Hayashi; Kazuko Ohno; Kazuo Awai; Toshinori Hirai; Kazuyuki Kojima; Shuji Sakai; Naofumi Matsunaga; Takamichi Murakami; Kengo Yoshimitsu; Toshifumi Gabata; Kenji Matsuzaki; Eriko Tohno; Yasuhiro Kawahara; Takeo Nakayama; Shuichi Monzawa; Satoru Takahashi
Journal:  Jpn J Radiol       Date:  2016-01       Impact factor: 2.374

Review 2.  Appearance of hepatocellular carcinoma on gadoxetic acid-enhanced hepato-biliary phase MR imaging: a systematic review.

Authors:  Paola Erra; Marta Puglia; Alfonso Ragozzino; Simone Maurea; Raffaele Liuzzi; Giuseppe Sabino; Luigi Barbuto; Alberto Cuocolo; Massimo Imbriaco
Journal:  Radiol Med       Date:  2015-04-22       Impact factor: 3.469

3.  Liver stiffness measured by magnetic resonance elastography as a risk factor for hepatocellular carcinoma: a preliminary case-control study.

Authors:  Utaroh Motosugi; Tomoaki Ichikawa; Tsuyota Koshiishi; Katsuhiro Sano; Hiroyuki Morisaka; Shintaro Ichikawa; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii; Tsutomu Araki
Journal:  Eur Radiol       Date:  2012-07-20       Impact factor: 5.315

Review 4.  Insight into hepatocellular carcinoma biology with gadoxetate disodium-enhanced MRI.

Authors:  Alexander Kagen; Kathryn Fowler; Claude B Sirlin
Journal:  Hepat Oncol       Date:  2013-12-20

5.  [Guideline compliant diagnostics of hepatocellular carcinoma].

Authors:  R R Plentz; B Boozari; N P Malek
Journal:  Radiologe       Date:  2014-07       Impact factor: 0.635

Review 6.  New paradigm for management of hepatocellular carcinoma by imaging.

Authors:  Ijin Joo; Byung Ihn Choi
Journal:  Liver Cancer       Date:  2012-09       Impact factor: 11.740

Review 7.  JSH Consensus-Based Clinical Practice Guidelines for the Management of Hepatocellular Carcinoma: 2014 Update by the Liver Cancer Study Group of Japan.

Authors:  Masatoshi Kudo; Osamu Matsui; Namiki Izumi; Hiroko Iijima; Masumi Kadoya; Yasuharu Imai; Takuji Okusaka; Shiro Miyayama; Kaoru Tsuchiya; Kazuomi Ueshima; Atsushi Hiraoka; Masafumi Ikeda; Sadahisa Ogasawara; Tatsuya Yamashita; Tetsuya Minami; Koichiro Yamakado
Journal:  Liver Cancer       Date:  2014-10       Impact factor: 11.740

8.  Was Hypervascular Hepatocellular Carcinoma Visible on Previous Gadoxetic Acid-Enhanced Magnetic Resonance Images?

Authors:  Shintaro Ichikawa; Tomoaki Ichikawa; Utaroh Motosugi; Katsuhiro Sano; Hiroyuki Morisaka; Nobuyuki Enomoto; Masanori Matsuda; Hideki Fujii
Journal:  Liver Cancer       Date:  2015-06-05       Impact factor: 11.740

9.  [Diagnosis of and therapy for hepatocellular carcinoma].

Authors:  T F Greten; N P Malek; S Schmidt; J Arends; P Bartenstein; W Bechstein; T Bernatik; M Bitzer; A Chavan; M Dollinger; D Domagk; O Drognitz; M Düx; S Farkas; G Folprecht; P Galle; M Geißler; G Gerken; D Habermehl; T Helmberger; K Herfarth; R T Hoffmann; M Holtmann; P Huppert; T Jakobs; M Keller; J Klempnauer; F Kolligs; J Körber; H Lang; F Lehner; F Lordick; A Lubienski; M P Manns; A Mahnken; M Möhler; C Mönch; P Neuhaus; C Niederau; M Ocker; G Otto; P Pereira; G Pott; J Riemer; K Ringe; U Ritterbusch; E Rummeny; P Schirmacher; H J Schlitt; K Schlottmann; V Schmitz; A Schuler; H Schulze-Bergkamen; D von Schweinitz; D Seehofer; H Sitter; C P Straßburg; C Stroszczynski; D Strobel; A Tannapfel; J Trojan; I van Thiel; A Vogel; F Wacker; H Wedemeyer; H Wege; A Weinmann; C Wittekind; B Wörmann; C J Zech
Journal:  Z Gastroenterol       Date:  2013-11-15       Impact factor: 2.000

Review 10.  How to Differentiate Borderline Hepatic Nodules in Hepatocarcinogenesis: Emphasis on Imaging Diagnosis.

Authors:  Hyun Jeong Park; Byung Ihn Choi; Eun Sun Lee; Sung Bin Park; Jong Beum Lee
Journal:  Liver Cancer       Date:  2017-03-09       Impact factor: 11.740

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.